Neha Patil (Editor)

Ablynx

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Traded as
  
ABLX

Website
  
www.ablynx.com

Founded
  
2002

Industry
  
Biotechnology

Headquarters
  
Ghent, Belgium

Ablynx wwwablynxcomassetsimagesablynxlogopng

Key people
  
Edwin Moses (CEO) Wim Ottevaere (CFO)

Stock price
  
ABLX (EBR) € 11.56 +0.04 (+0.39%)28 Feb, 3:59 PM GMT+1 - Disclaimer

Profiles

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies.

Contents


History

In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2M was provided by Gimv.

In July 2015 Merck & Co. and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx. In 2015, the Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.

References

Ablynx Wikipedia